Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ad.2022.05.044 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early Reduction of FeNO on Anti-IL5 Biologics Is Associated With Clinical Remission of Severe Asthma.
Allergy
December 2024
Department of Respiratory Medicine, Copenhagen University Hospital-Bispebjerg, Copenhagen, Denmark.
Background: In patients with severe asthma, treatment with anti-interleukin-5 (IL-5) biologics can lead to a reduction in fractional exhaled nitric oxide (FeNO) in some patients. The clinical implications of varying FeNO responses to anti-IL-5 biologics remain unclear. This study aims to categorise patients based on their FeNO response to anti-IL-5 biologics and evaluate the association of these categories with clinical outcomes.
View Article and Find Full Text PDFClinical, Immunologic, and Genetic Characteristics in Patients With Syndrome of Undifferentiated Recurrent Fevers.
Arthritis Rheumatol
December 2024
University of Cincinnati and Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Objective: Syndrome of undifferentiated recurrent fevers (SURF) is characterized by recurrent fevers and autoinflammation without a confirmed molecular diagnosis of a hereditary recurrent fever syndrome, and not fulfilling criteria for periodic fever, adenitis, pharyngitis, aphthous stomatitis syndrome (PFAPA). The goal of this study was to characterize clinical features of patients with SURF compared to patients with PFAPA and to analyze their cytokine signature, genetic variations, and responses to treatment.
Methods: We enrolled 46 patients observed at Cincinnati Children's Hospital Medical Center.
Urticarial vasculitis.
Curr Opin Rheumatol
January 2025
Marmara University School of Medicine, Department of Dermatology, Istanbul, Türkiye.
Article Synopsis
- Urticarial vasculitis (UV) is a rare condition that can range from mild skin issues to serious systemic problems, and recent research focuses on its causes, diagnosis, and treatment options.
- New triggers for UV associated with SARS-CoV-2 and COVID-19 vaccines have been noted, along with a new clinical-dermoscopic method for diagnosis that reduces reliance on skin biopsies.
- Treatments such as antihistamines, corticosteroids, and rituximab show promise for success and long-lasting remission, while epidemiological studies show good survival rates but highlight certain severe health issues that can increase mortality.
Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan.
Eur J Dermatol
October 2024
Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Niazi, Japan.
Article Synopsis
- Tralokinumab, a human monoclonal antibody, is an approved treatment for atopic dermatitis (AD) and was evaluated for its effectiveness and safety in Japanese patients between October 2023 and March 2024.
- In a study involving 103 patients, significant improvements in eczema severity were observed at weeks 4 and 12, including notable reductions in the Eczema Area and Severity Index (EASI) scores and itch intensity.
- The treatment was generally well-tolerated, with mild and manageable side effects reported in 14.8% of patients, including a low incidence of conjunctivitis that resolved on its own.
Advances in the management of psoriatic arthritis in adults.
BMJ
November 2024
University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, ON, Canada
Article Synopsis
- * Management starts with assessing the patient's skin and joints while screening for other health issues, followed by a mix of therapies like education, lifestyle changes, and physiotherapy.
- * Treatment options include non-steroidal anti-inflammatory drugs and disease-modifying therapies such as methotrexate and biologics, but there’s a need for better biomarkers to personalize these treatments for each patient.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!